Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.

BMC Med · 2022 · PMC9795751 · PMID 36575513

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Compared with lapatinib plus capecitabine, pyrotinib plus capecitabine exhibited an over 20% increase in objective response rate (ORR), a significant benefit in progression-free survival (median, 12.5 versus 6.8 months; hazard ratio [HR], 0.39), and a clear trend towards improvement in overall survival (median, not reached versus 26.9 months; HR, 0.69) in patients with pretreated metastatic HER2-positive breast cancer [ 12 – 14 ].

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.